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ABSTRACT 
 
The small G protein Rap1 regulates diverse cellular processes such as integrin activation, cell 
adhesion, cell-cell junction formation and cell polarity. It is crucial to identify Rap1 effectors to 
better understand signalling pathways controlling these processes. Krit1, a FERM protein, was 
identified as a Rap1 partner in a yeast two-hydrid screen, but this interaction was not confirmed 
in subsequent studies. As evidence suggests a role for Krit1 in Rap1-dependent pathways, we 
readdressed this question. Here, we demonstrate by biochemical assays that Krit1 is a specific 
Rap1 effector. We show that, like other FERM proteins, Krit1 adopts two conformations: a 
closed conformation in which its N-terminal NPAY motif interacts with its C-terminus and an 
opened conformation bound to ICAP-1, a negative regulator of focal adhesion assembly. We 
show that a ternary complex can form in vitro between Krit1, Rap1 and ICAP-1 and that Rap1 
binds Krit1 FERM domain in both closed and opened conformations. Unlike ICAP-1, Rap1 does 
not open Krit1. Using sedimentation assays, we show that Krit1 binds in vitro to microtubules 
through its N and C-termini and that Rap1 and ICAP-1 inhibit Krit1 binding to microtubules. 
Consistently, YFP-Krit1 localizes on CFP-labelled microtubules in BHK cells and is delocalized 
from microtubules upon co-expression with activated Rap1V12. Finally, we show that Krit1 
binds to PIP2 containing liposomes and that Rap1 enhances this binding. Based on these results, 
we propose a model in which Krit1 would be delivered by microtubules to the plasma membrane 
where it would be captured by Rap1 and ICAP-1. 
 
 
Keywords: Rap1, Krit1, CCM1, FERM domain, PTB, microtubules, PIP2 
The abbreviations used are: MT: microtubules, Krit1: Krev Interaction Trapped gene, CCM1: 
cerebral cavernous malformation 1, ICAP-1: Integrin Cytoplasmic Domain Associated Protein, 
PTB: Phosphotyrosine-binding domain, FERM: band Four-point-one/Ezrin/Radixin/Moesin 
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INTRODUCTION 
 
The small G protein Rap1 (Krev-1), a member of the Ras superfamily, has been brought to the 
forefront since the discovery that it regulates diverse cellular processes such as integrin 
activation and cell adhesion, cell spreading, cell polarity and cell-cell junction formation 
[1],[2],[3]. To gain more insights into these pathways, a variety of effector proteins that interact 
with active Rap1GTP-bound form has been identified. Among them, RAPL, which is enriched in 
lymphoid tissues, activates the integrin αLβ2, most likely by interacting with αL integrin [4] and 
RIAM, which binds to different actin regulators, participates in an integrin activation complex 
that binds to and activates β integrins [5]. VAV1 and TIAM1 are localized by Rap1GTP to sites 
of cell spreading and serve as exchange factors for Rac [6]. ARAP3 is a GTPase-activating 
protein for RhoA and Arf6 that affects PDGF-induced lamellipodia formation [7]. In 
dictyostelium, Phg2 promotes myosin II disassembly at the front of chemotaxing cell facilitating 
filamentous-actin mediated leading edge protrusion [8]. Afadin/AF6 participates in the 
maturation of cell-cell junctions [9]. 
Krit1 (Krev Interaction Trapped gene) was identified in 1997 as a Rap1 partner in a yeast two-
hydrid screen [10], but subsequent studies did not confirm their interaction [11], leading to the 
conclusion that Krit1 is not a Rap1 partner [12]. However, several pieces of evidence concerning 
a potential role of Krit1 in Rap1-regulated cellular processes prompted us to reconsider this 
question. First, it has recently been demonstrated that Rap1-dependent activation of integrins 
requires talin binding to the cytoplasmic tail of β integrin [13]. Talin is an essential integrin-
activating protein that connects the cytoplasmic tail of β integrins to the actin cytoskeleton [14]. 
ICAP-1 (Integrin Cytoplasmic Domain Associated Protein) is a partner of the cytoplasmic tail of 
β1 integrin and it has been shown to compete with talin for binding to β1 integrin [15]. 
Consistently, on ICAP-1-null osteoblasts and fibroblasts, fibronectin receptors are in an active 
conformation and β1-dependent cell adhesion is enhanced compared to that of wild-type cells 
[16],[17].On the opposite, overexpression of ICAP-1 reduces cell spreading and disorganizes 
focal adhesions [15]. These results suggest that at resting state, β1 integrin is kept inactive 
through binding of ICAP-1 to its cytoplasmic tail. Interestingly, Krit1 is a partner of ICAP-1 
[11], [18]. Yeast-two hydrid studies have shown that Krit1 competes with β1 integrin for binding 
to ICAP-1 [11], suggesting that Krit1 could relieve the inhibitory effect of ICAP-1 on β1 integrin 
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activation. The second piece of evidence concerns the existence of a human genetic disease 
linked to mutations in Krit1 gene. CCM1 (cerebral cavernous malformation 1) corresponds to 
brain capillaries malformations characterized by clusters of dilated thin-walled blood vessels 
[19]. These lesions usually hemorrhage resulting in seizures, focal neurological deficits or stroke. 
Ultrastructural studies show that tight junctions are absent between the endothelial cells in these 
lesions and that the surrounding basal lamina is hypertrophied [20]. 
Very little is known about the Krit1 protein and its subcellular localization. First, Krit1 C-
terminus amino acid sequence bears homologies with FERM domains (present in band Four-
point-one/Ezrin/Radixin/Moesin). FERM domains localize proteins to the plasma membrane, 
where they can interact with phosphoinositides and membrane proteins [21]. The FERM domain 
of talin interacts with phosphatidylinositol 4, 5-P2 (PIP2) and with the cytoplasmic tail of β 
integrins [14]. Moreover, proteins with FERM domains usually exist in two conformational 
states: a closed “inactive” conformation where the FERM domain is masked by another part of 
the protein and an open “active” conformation where the FERM domain is unmasked. Cleavage, 
phosphorylation or (PIP2) binding are activation signals [21]. Second, it has been reported that 
Krit1 interacts with tubulin in BAEC and decorates microtubules all along their length [22]. 
However, this interaction has been questioned because the antibody used in this study recognized 
a protein of lower size on western blot. Another antibody has since identified a protein of the 
predicted size, but the primary location of Krit1 awaits elucidation [39]. Since microtubules are 
known to regulate the dynamics of focal adhesion assembly [23],[24], we readressed this 
important issue. 
In this paper, we sought for the interaction of Krit1 with Rap1, microtubules and membranes. We 
show that Krit1, like many proteins with FERM domains, adopts a closed conformation. This 
closed conformation is opened by ICAP-1. Importantly, we confirm that Krit1 interacts 
specifically with Rap1 and preferentially with active Rap1 (GTP-bound form), ending the debate 
about this point. We show that Rap1 binds to the FERM domain of Krit1 both in its closed and 
opened conformations and that, unlike ICAP-1, Rap1 does not open Krit1. Moreover, we 
demonstrate that Krit1, Rap1 and ICAP-1 can form a ternary complex in vitro. We show that 
Krit1 interacts with in vitro polymerized microtubules, and with PIP2 on artificial membranes. 
Remarkably, we demonstrate that Rap1 and ICAP-1 inhibit in vitro Krit1 binding to 
microtubules and that Rap1 stimulates Krit1 binding to membranes. Consistently, YFP-Krit1 
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localizes on CFP-labelled microtubules in BHK cells and is delocalized from microtubules upon 
co-expression with activated Rap1. 
 
RESULTS 
 
Krit1contains a putative FERM domain and binds to PIP2 
Tri-dimensional structure of the FERM domain of the archetypal ERM proteins, ezrin, radixin 
and moesin, have been resolved by crystallography [25],[26],[27]. They are composed of three 
sub-domains F1 to F3 arranged in a clover-shaped fashion (Fig. 1A). F3 sub-domain resembles a 
PTB domain, a conserved structural fold that binds to protein NPxY motifs [28]. Analysis of 
Krit1 sequence using Blast program shows that the last 300 amino acid residues of Krit1 bear 
roughly 20% identity with F1, F2, F3 sub-domains of the typical ERM proteins (ezrin, radixin, 
moesin, talin). Even though this is the lower limit for comparative modelling, we were able to 
generate models for Krit1 F1 and F2-F3 sub-domains structure based on the homology with 
radixin F1 in complex with IP3 and with talin F2-F3. (Fig. 1B). These models displayed very 
stable secondary structures and energies throughout molecular dynamics simulations, strongly 
supporting the idea that Krit1 C-terminus folds as a FERM domain. 
A functional feature of FERM domains is their capacity to interact with PIP2 on plasma 
membrane. In the radixin-IP3 co-crystal, IP3 binds to a basic cleft located between F1 and F3 
sub-domains and folded around a tryptophan present at the hydrophobic base of the cleft [26] 
(Fig. 1A). Interestingly, on our model of the Krit1 FERM domain, basic residues are also found 
in the cleft between sub-domain F1 and F3 and the tryptophan at the base of the pocket is 
conserved (Fig. 1B), implying that Krit1 would have the structural features required for binding 
to phospho-inositides on membranes. We therefore tested the ability of Krit1 to binding to PIP2 
containing membranes. Krit1 was incubated with artificial liposomes supplemented or not with 
2% PIP2 at increasing NaCl concentrations. At 100 mM NaCl, 70 % of Krit1 bound to PIP2 
containing liposomes, whereas less than 10% bound to liposomes without PIP2, showing that 
Krit1 interacts mainly with PIP2 on these liposomes (Fig. 1C). Moreover, increasing salt 
concentrations decreased Krit1 binding, highlighting the electrostatic status of this interaction 
(Fig. 1C).  
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Krit1 exists in a closed conformation opened by ICAP-1. 
Intriguingly, in addition to its C-terminal FERM domain, Krit1 has a NPAY motif on its N-
terminus that binds to ICAP-1 [11], [18]. This peculiarity of Krit1 led us to ask whether this 
motif could interact with Krit1 F3 PTB-like sub-domain. To test this hypothesis, we separately 
expressed His-tagged N-terminus (1 to 207 aa) and GST-C-terminus (207-end), which we called 
Krit1-NTer and GST-HypoKrit1, respectively (Fig. 2A). GST pull-down assays were performed 
by mixing these two fragments at a concentration of 100 nM each. Remarkably, Krit1-NTer 
bound specifically to GST-HypoKrit1 and to GST-ICAP-1 used as a positive control, but it did 
not bind to GST alone (Fig. 2B). To test whether the NPAY motif is involved in this interaction, 
we mutated Asn192 and Tyr195 into alanines in Krit1-NTer (Fig. 2A). Krit1-NTer APAA 
mutant did not interact with GST-HypoKrit1 and interacted only very weakly with GST-ICAP-1 
as previously reported [11] (Fig. 2B). In an other assay, ICAP-1 totally prevented the binding of 
Krit1-NTer (5 µM) to GST-HypoKrit1 (3.5 µM) when added at equimolar concentration with 
Krit1-Nter (Fig. 2C), which correlates well with the observation that ICAP-1 had a better affinity 
for Krit1-Nter than HypoKrit1 (Fig. 2B). 
These results show that Krit1 C-terminal FERM domain interacts with Krit1 N-terminus in vitro, 
and that this interaction requires the ICAP-1 binding motif NPAY. They suggest that full-length 
Krit1 exists in a closed conformation with the N-terminus folded on the C-terminus and that 
ICAP-1 binding to the N-terminal part disrupts Krit1 N and C-termini interaction. 
 
Krit1 interacts with Rap1 preferentially in its GTPγS bound form. 
To answer the question of whether Krit1 is a Rap1 effector, i. e. whether Krit1 interacts 
preferentially with Rap1 in its GTP-bound form, we performed GST-pull down assays. Since we 
could not purify GST-full-length Krit1 because of its insolubility in E.Coli, we studied the 
binding of Rap1 to GST-HypoKrit1. We compared the binding of 1 μM of Rap1 loaded with 
GDP or GTPγS to 10 μM of GST-HypoKrit1 by GST pull-down experiments. Unless specified, 
all the experiments were performed with Rap1A isoform. Rap1 binding to HypoKrit1 was 
specific, as no binding was observed to GST. Rap1GTPγS bound twice more strongly to 
HypoKrit1 than did Rap1GDP, reflecting a higher affinity of active Rap1 for HypoKrit1 (Fig. 
3A). In the same assay conditions, H-Ras GTPγS did not bind to HypoKrit1 (Fig. 3A). This 
experiment therefore shows that Krit1 is a specific effector of Rap1. 
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Rap1 binds to the C-terminus of Krit1. 
Serebriiskii et al. mapped a binding site for Rap1 in the 50 last a.a residues of the N-truncated 
form of Krit1 that they originally identified [10]. To verify this result, this site was deleted in 
GST-HypoKrit1 (Fig 2A). The resulting GST-HypoKrit1ΔC mutant has a truncation of half of its 
F3 subdomain. We used the same experimental conditions as in figure 3A. Deletion of the C-
terminus of Krit1 abolished the binding of Rap1GTPγS to GST-HypoKrit1(Fig. 3B), confirming 
that Rap1 binds to Krit1 C-terminal FERM domain. 
 
Krit1, Rap1, and ICAP-1 form a ternary complex in vitro. 
Since Krit1 can interact independently with ICAP-1 and with Rap1, we tested whether a ternary 
complex can form between the three proteins. We purified His-tagged full-length Krit1 from E. 
Coli and we performed GST pull-downs by mixing full-length Krit1 with Rap1GTPγS and GST-
ICAP-1 at a final concentration of 5 µM each (Fig. 4). Krit1 interacted specifically with GST-
ICAP-1 and not with GST alone. This interaction was strong enough to be revealed by staining 
of the proteins with Sypro Orange. As expected, Rap1GTPγS did not interact with GST-ICAP-1 . 
Interestingly, when Krit1 and Rap1GTPγS were added together, Rap1GTPγS was pulled-down 
with Krit1 on GST-ICAP-1 beads. Immunoblotting of Rap1 was necessary to reveal Rap1 
binding, indicative of a weaker interaction of Krit1 with Rap1 than with ICAP-1. Therefore, this 
experiment shows that the three proteins form a ternary complex in vitro. 
 
Rap1 binds equally to Krit1 opened and closed conformations and does not open Krit1. 
Next, we compared the binding of Rap1 to Krit1 closed and opened conformations. To do so, we 
measured by GST-pull down the binding of 10 µM of Rap1 GTPγS on 3 µM of GST-HypoKrit1 
beads in absence or presence of 10 µM of Krit1-NTer. Importantly, Krit-NTer binding to GST-
HypoKrit1 did not affect the interaction of Rap1GTPγS to GST-HypoKrit1 (Fig. 5A). 
Conversely, Rap1 did not modify the binding of Krit1-NTer to HypoKrit1, suggesting that Rap1 
binds to Krit1 closed conformation and does not open it. Moreover, the binding of Rap1GTPγS 
to GST-HypoKrit1 was not modified either when the complex between HypoKrit1 and Krit1-
NTer was disrupted by the addition of 10 µM of ICAP-1, implying that the opening of Krit1 by 
ICAP-1 does not affect Rap1 binding (Fig. 5A). This result was confirmed on full length Krit1 
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by FLAG-pull-down experiment using FLAG-tagged Krit1. Addition of ICAP-1 together with 
Rap1 did not change Rap1 binding to Krit1 (Fig. 5B). Therefore, Rap1 and ICAP-1 can bind 
independently to Krit1. All together, our results suggest that, unlike ICAP-1, Rap1 binding to the 
C-terminal FERM domain does not induce the opening of Krit1 and that Rap1 binds as well on 
Krit1 closed and opened conformations (Fig. 5C). 
 
Krit1 interacts in vitro with microtubules via two sites present respectively on its N- and C-
termini. 
It has previously been shown that Krit1 colocalizes with microtubules in BAEC [22]. However, 
the antibody used in these studies recognizes a 58 kDa protein on western blot which could 
correspond either to a shorter splice variant of Krit1 or to another protein. To address this 
question, we studied by sedimentation on sucrose cushion the binding of purified His-tagged 
full-length Krit1 to in vitro polymerized microtubules (MT). When 40 pmoles of full-length 
Krit1 were incubated with MT polymerized from 200 pmoles of purified tubulin, 60% of the 
protein co-sedimented with MT (Fig. 6A), demonstrating a direct interaction of Krit1 with MT. 
Remarkably, the contaminant proteins contained in Krit1 preparations, even those present at the 
same concentration as Krit1, did not co-sediment with MT (Fig. 6A), highlighting the specificity 
of Krit1 interaction with MT. To map the domain responsible for this interaction, we studied the 
binding of different fragments of Krit1 in the same conditions. Krit1-NTer fragment bound 
strongly to MT (45%). Krit1 bears a basic stretch of six lysines and arginine on its N-terminus 
which could interact with MT. Mutations of amino acids 47KKRK50 in four alanines almost 
completely abolished Krit1 binding to MT (Fig. 6A) whereas this mutant was still able to interact 
with ICAP-1 (data not shown). GST-HypoKrit1 also interacted with MT. However, by contrast 
to full-length Krit1 and Krit1-NTer, only 20% of GST-HypoKrit1 bound to MT (Fig. 6A). In 
control, GST alone did not bind to MT (Fig. 6B). The truncation in the F3 sub-domain of GST-
HypoKrit1 almost completely abolished the co-sedimentation of GST-hypoKrit1ΔC with MT 
(Fig. 6A). Thus two sites are responsible for the interaction of Krit1 with microtubules: a basic 
stretch of residues located in the N-terminal part of the protein centered on residues 46 to 50 with 
high affinity for MT and a second site located on the F3 sub-domain with low affinity for MT. 
 
Rap 1and ICAP-1 inhibit in vitro Krit1 binding to microtubules. 
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Having shown that MT bind to the N- and C- termini of Krit1, we asked whether ICAP-1 or 
Rap1, which bind respectively to Krit1 N- and C-termini, could modulate Krit1 interaction with 
MT. Thus, we measured the binding of 40 pmoles of Krit1 to MT in presence of 200 pmoles of 
Rap1GTPγS or GST-ICAP-1. Rap1GTPγS alone was not recruited to MT and less than 10% of 
GST-ICAP-1 bound to MT (Fig. 6B). Remarkably, both Rap1GTPγS and GST-ICAP-1 inhibited 
Krit1 binding to MT whereas GST alone had no effect (Fig. 6B). Similar inhibition was obtained 
using Rap1B isoform (data not shown). However, ICAP-1 was a more potent inhibitor than 
Rap1GTPγS at these concentrations (80 % inhibition versus 50%). It is unlikely that ICAP-1 
effect would be due to a competition with Krit1 for binding to MT since only 20 pmoles of GST-
ICAP-1 bound to the 150 pmoles of tubulin, polymerized in MT, leaving around 130 pmoles of 
tubulin available for interaction with Krit1. 
 
YFP-Krit1 co-localizes with CFP-labelled microtubules in transfected BHK cells and is 
delocalized from microtubules by activated Rap1. 
To confirm our in vitro results in a cellular context, we co-expressed Krit1 fused to YFP together 
with CFP-tubulin in BHK cells. While YFP-ARNO signal, used as a negative control, was 
diffuse in the cytosol, YFP-Krit1 signal was superimposable to the CFP-labelled microtubules 
signal indicating that YFP-Krit1 was localized along microtubules from MTOC to periphery. Co-
expression of activated mutant of Rap1, HA-Rap1V12, flattened the cells which became spread 
and displayed numerous membrane spikes, a phenotype also observed with HA-Rap1V12 alone 
(data not shown). Remarkably, YFP-Krit1 was no longer co-localized with CFP-labelled 
microtubules in Rap1V12 expressing BHK cells. Thus, these experiments support our in vitro 
observations that Krit1 binds to microtubules and that this binding is inhibited by Rap1GTP .  
 
Rap1 enhances HypoKrit1 binding to asolectin vesicles. 
An other feature of Krit1 is its capacity to bind to phospholipids. We wondered whether Rap1, 
which binds to Krit1 FERM domain, could modulate Krit1 association with membranes. 
Remarkably, when 3 µM of Rap1GTPγS were added to 0.5 µM GST-HypoKrit1, we observed a 
stimulation of GST-HypoKrit1 binding to asolectin vesicles, (Fig. 8A). A fraction of 
Rap1GTPγS also sedimented with the vesicles. Since the recombinant unmodified Rap1 that we 
used did not bind to lipids by itself (Fig.8A), this fraction actually corresponds to Rap1 
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complexed with HypoKrit1 (Fig. 8A). Moreover, the stimulation of GST-HypoKrit1 binding to 
asolectin vesicles by Rap1GTPγS was dose-dependent, up to 6-fold (Fig. 8B). 
 
DISCUSSION 
 
In this paper, we confirm that Krit1 specifically interacts in vitro with Rap1 and preferentially 
with active Rap1 (GTP-bound form), the criteria for Krit1 being a “bona-fide” effector of Rap1. 
We show for the first time that Krit1 exists in a closed conformation in which its N-terminus 
interacts with its C-terminus. ICAP-1 binding to the N-terminal NPAY motif disrupts this 
interaction, whereas Rap1 binding to the C-terminal FERM domain does not. Moreover, we 
show that Krit1, Rap1 and ICAP-1 can form a ternary complex in vitro.  
Krit1 binds in vitro to microtubules via two sites on its N and C-termini. Remarkably, Rap1 and 
ICAP-1 inhibit in vitro Krit1 binding to microtubules. In transfected BHK cells, YFP-Krit1 
localizes along CFP-labelled microtubules and is delocalized from microtubules by co-
expression of activated Rap1V12. Finally we show that Krit1 binds to phospholipids on 
membranes and that Rap1 enhances this binding. 
 
Krit1 is an effector of Rap1  
Our detailed biochemical study demonstrates that Krit interacts specifically with Rap1 ending the 
debate about this question. Indeed, both N-truncated Krit1, which we called HypoKrit1, 
(corresponding to the yeast two-hybrid Rap1 partner originally identified) and the full-length 
protein interact with Rap1, as shown by pull-down and asolectin vesicle sedimentation 
experiments. Moreover, HypoKrit1 interacts with a higher affinity with Rap1GTPγS than with 
Rap1GDP, indicating that Krit1 is a downstream effector of Rap1. Similar results were obtained 
with FLAG-tagged full-length Krit1 (data not shown). Our results differ substantially from those 
of Zhang et al who failed to observe an interaction between the two proteins [11]. This 
discrepancy might be related to the methods applied. These authors used in vitro translation of 
Rap1 and Krit1. The amount of proteins produced might not be sufficient for co-
immunoprecipitation, since micromolar concentrations of the two proteins were necessary in our 
hands to observe a complex. Consistently, an interaction of low affinity (Kd=4.7 µM) was found 
between Krit1 and Rap1B, a very close homolog of Rap 1A [29]. We did not detect any 
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interaction of H-Ras with Krit1 as previously reported [10], [30], [29]. Thus, it appears that Krit1 
is a specific effector of Rap1, suggesting that it is involved in a Ras-independent, Rap1-
dependent pathway. Even though it has been proposed that Rap1 may bind to Krit1 F1 sub-
domain because this sub-domain bears homology with a computerized model of Ras Binding 
Domain (RBD) [31], the absence of interaction between HypoKrit1ΔC and Rap1 rather suggests 
that Rap1 interacts with the PTB-like F3 sub-domain. Similarly, talin and radixin FERM 
domains interact via their F3 sub-domain with respectively integrin and ICAM-2 cytoplasmic 
tails, as shown by co-crystal structures [32],[33]. Further mutagenesis studies will be necessary 
to map precisely the site for Rap1 interaction on Krit1 FERM domain.  
 
Krit1, like other FERM proteins, adopts closed and opened conformations and binds to PIP2 
The molecular modeling of the last 300 amino acid residues of Krit1 that we generated 
corroborates the existence of a FERM domain at the C-terminus of the protein. FERM domains 
are involved in localizing proteins to the plasma membrane. It has been shown by sedimentation 
experiments and crystallographic studies that they bind to PIP2 (for instance radixin [30], talin 
[34]) via the interaction of the polar head of the lipid with a basic cleft present between F1 and 
F3 sub-domains. Consistently, we show that Krit1 binds to PIP2. Interestingly, several basic 
residues are exposed to the F1-F3 cleft on the Krit1 FERM model that we generated. 
Mutagenesis analyses of these residues will help to determine whether the binding site of the 
polar head of PIP2 on Krit1 is similar to that of radixin. 
Many members of the FERM family undergo intra- and/or inter- molecular folding of their C-
terminus onto their N-terminal FERM domain [21]. Consistently, we demonstrate the interaction 
of the N-terminus of Krit1 with its C-terminus, both parts being produced separately. Cis or trans 
interaction between these two domains are equally possible and would lead to either an intra-
molecular folding in a closed conformation or an intermolecular folding in an anti-parallel homo-
dimer like talin. Furthermore, we have shown that the N-terminal NPAY motif is involved in the 
interaction, which suggests that the PTB-like F3 sub-domain of the FERM is the C-terminal 
counterpart. As such, in the dormant form of moesin, F3 sub-domain is masked by the N-
terminal extended actin binding tail domain [27]. Moreover, we show that ICAP-1 binding 
disrupts Krit1 N and C-termini interaction. This interaction, as well as its disruption by ICAP-1, 
could be verified on the full-length protein by fluorescence resonance energy transfer (FRET) of 
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Krit1 fused to YFP and CFP at its extremities. This could represent a crucial mechanism of 
regulation of Krit1 activity. Indeed, both NPAY motif and PTB-like F3 sub-domain are binding 
sites for other partners, such as ICAP-1, phospholipids and yet unknown partners most likely 
trans-membrane or peri-membrane proteins. Masking of these two sites may prevent Krit1 to 
interact with other proteins until it is delivered to its target (s). It has been shown that Krit1 
interacts with the CCM2 gene product malcavernin, a PTB domain protein, in the context of a 
Rac/MEKK3/MKK3 signalling complex which activates p38 MAPK kinase [35]. Krit1-CCM2 
interaction does not involve the NPAY motif and a ternary complex can form between Krit1, 
CCM2 and ICAP-1. It is possible that Krit1, through its interaction with different partners on the 
plasma membrane, participates in several but linked signalling pathways involved in 
angiogenesis [35]. 
 
Rap1 and ICAP-1regulate Krit1 localization to microtubules and membranes 
Among the FERM family members, ERM proteins and talin provide a regulated linkage between 
membrane proteins and the cortical actin cytoskeleton. No actin-binding site has been reported 
on Krit1. Consistently, purified Krit1 does not interact with in vitro polymerized actin (Eric 
Macia, personal communication) nor does YFP-Krit1 localize in cells to phalloidin-labelled F-
actin (data not shown). Instead, we confirm the previous report that Krit1 is a microtubule-
associated protein [22] by showing that it co-localizes with microtubules in cells and that it 
interacts directly with in vitro polymerized microtubules. Moreover, our results show that Krit1 
binds to MT through two sites: one basic site in the N-terminal part of the protein located on 
residues 46 to 51 with high affinity for MT and a second on the C-terminus in the F3 sub-domain 
with low affinity for MT. The N-terminal basic motif has also been described as a functional 
nuclear localization sequence [39], suggesting that it could be involved in the shuttling of Krit1 
between the microtubules and the nucleus. Remarkably, the contribution of these two sites to the 
binding to MT is additive (Fig. 6A). Since we show that the N-terminus of Krit1 interacts with 
the C-terminus, it is most likely that these two MT binding sites actually form a continuous 
surface on the closed protein. We show that ICAP-1 and Rap1 both inhibit the binding of Krit1 
to MT. Two hypotheses can be proposed concerning the mechanism of this inhibition. The first 
one is that they directly mask the surface that binds to MT. Indeed our results show that MT and 
Rap1 both bind to the last fifty residues of Krit1. It is not so clear for the basic stretch which lies 
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between residues 46 to 51.  ICAP-1 binds further on the primary sequence on the 191NPAY194 
motif. It is possible however that these two sites are actually close in the folded protein. The 
second hypothesis is that ICAP-1 binding provokes structural changes of the basic site that lead 
to a decrease of its affinity for MT. Nevertheless, the fact that ICAP-1 is a more potent inhibitor 
than Rap1 correlates well with, for one part, its stronger binding to Krit1 at the micromolar 
concentrations used in these experiments and, for the second part, with the higher contribution to 
the binding to MT of the basic stretch than the C-terminal site. 
At the cell periphery, Rap1 shuttles between recycling endosomes and the plasma membrane, its 
GTP form being localized at the plasma membrane [36]. Interestingly, we show that Rap1GTPγS 
stimulates HypoKrit1 binding to artificial membranes. HypoKrit1 is not recruited to membranes 
through Rap1 because the unmodified Rap1 that we used does not bind to membranes. Instead, 
Rap1 binding to Krit1 FERM domain most likely induces a conformational change of the PIP2 
binding pocket that gives HypoKrit1 a better affinity for PIP2. Our attempts to observe Rap1 
stimulation of full-length Krit1 binding to asolectin vesicles were not successful even in the 
presence of ICAP-1, whose binding should unmask Krit1 FERM domain (data not shown). 
Several experimental caveats may be responsible for this negative result. In absence of its C-
terminal lipid anchor, Rap1 positioning toward Krit1 and the membrane may not be optimized 
and therefore the complex not fully stabilized. Moreover ICAP-1 may not be sufficient to 
stabilize Krit1 in its opened conformation. Interaction with another partner may be required for 
the protein to be stably opened. 
Krit1 localization on microtubules and its delocalization by activated Rap1 is very similar to  
reported results on RAPL, another Rap1 effector. Indeed, RAPL also localizes on MT in 
endothelial cells and directly binds to in vitro polymerized MT [37].  In wound healing assays, 
RAPL localizes on MT oriented toward the leading edge, an area where Rap1 is highly activated 
and its interaction with Rap1 is required for directional migration [37]. Moreover, co-expression 
of  Rap1V12 also induces dissociation of RAPL from MT [37].  In lymphocytes, RAPL moves 
dynamically from the peri-nuclear region to the leading edge upon chemokine stimulation and 
activated Rap1 triggers the association of RAPL with αLβ2 leading to the redistribution of this 
integrin to the immunological synapse [4]. In addition to integrin activation, Rap1 induces cell 
polarization and facilitates cell migration. Expression of activated Rap1 polarizes lymphocytes, 
generating a leading edge at the front and a uropod at the back. It also stimulates lymphocyte 
in
se
rm
-0
03
22
43
5,
 v
er
sio
n 
1 
- 1
7 
Se
p 
20
08
 14
endothelium transmigration [38] and directional migration of endothelial cells [37]. Therefore, 
delivery of Rap1 effectors to focal adhesions by the MT network might participate in the 
polarized activation of integrins. In line, targeting of MT in close vicinity of adhesion foci on the 
plasma membrane has been reported [39], as well as regulation of the turn-over of focal 
adhesions by MT [23], [24]. Based on our results, we propose a model of regulation of Krit1 
binding to MT and plasma membrane; in the cell, Krit1 would be transported in its closed 
conformation along MT toward the plasma membrane. When reaching the membrane, Krit1 
would detach from MT and be captured by activated Rap1 and ICAP-1 on the plasma membrane 
(Fig. 9). In the absence of ICAP-1, Rap1GTP would bind to Krit1 favouring its detachment from 
the MT and its binding to the plasma membrane without, however, opening it. This complex 
could serve as a stock for a rapid delivery of Krit1 to its target sites on the plasma membrane.  
An important breakthrough in unraveling the Rap1-dependent pathway in integrin activation has 
been achieved recently by Han et al [13]. Their work demonstrates that Rap1 promotes talin 
binding to the cytoplasmic tail of β3 and β1 integrins. They show that Rap1 induces the 
formation of an integrin activation complex which contains talin and RIAM, a Rap1 effector. 
RIAM is known to bind to profilin and Ena/VASP [5] suggesting that it could participate in actin 
network formation at the level of focal adhesion [13]. 
Concerning activation of β1 integrin per se, i. e. its switch to high affinity conformation, our 
present data and Han’s lead us to hypothesize that this Rap1-dependent activation complex could 
contain Krit1. Its binding to ICAP-1 would displace ICAP-1 from its inhibitory site on β1 
integrin, therefore allowing talin binding and subsequent β1 conformational changes. Further 
work is in progress to determine whether Krit1 is targeted by the microtubule network to focal 
adhesions and whether Rap1, RIAM and ICAP-1 regulate this localization. Furthermore, 
functional studies will investigate the role of Krit1 on cell adhesion to determine whether Krit1 is 
involved in the Rap1-dependent integrin activation pathway. 
 
MATERIAL AND METHODS 
 
Plasmid constructions - pcDNA4/V5-HISA-FLAG-Krit1 and pCDNA4/V5-HISA-FLAG-ICAP-
1 were kindly provided by D.A. Marchuk (Duke University Medical Center, Durham, NC). Krit1 
was sub-cloned in pET21d (Novagen, Fontenay-sous-Bois, France) and pEYFP-N1 (Clontech, 
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Saint-Germain-en-Laye, France), HypoKrit1 (208 to 736) in pGEX-2T (Roche Diagnostics, 
Meylan, France). Krit1-Nter (1-207) was sub-cloned in pQE 30 (Qiagen) and pETGEX-CT 
(National Institute of Genetics, Japan). Asn192Ala-Tyr195Ala substitutions, alanine 
substitutions of 47KRKK50 and introduction of a stop codon at aa 686 were produced using the 
QuikChange mutagenesis kit (Stratagene, Amsterdam, The Netherlands). pMT2-HA-Rap1A and 
pMT2-HA-Rap1AV12 were kindly provided by J. L. Bos (University Medical Center, Utrecht, 
The Netherlands). C-terminal-deleted (1-167) Rap1A was sub-cloned into pET16b (Novagen). 
ICAP-1 was sub-cloned in pGEX-2T. 
Purification of recombinant proteins - The expression of Krit1 and Krit1 KRKK/AAAA in 
Escherichia. coli BL21(DE3)codon+ cells (Stratagene) was induced at an optical density 
(OD600) of 0.8 with 0.2 mM isopropyl-β-D thio-galactopyranoside and grown for an additional 
16 h at 18°C. His-tagged Rap1, His-tagged Krit1-Nter WT and APAA, GST-HypoKrit1, GST-
HypoKrit1ΔC, Krit1-Nter-GST, and GST-ICAP-1 were produced in Escherichia. coli Bl21 gold 
(Stratagene) induced with 0.2 mM IPTG at OD 0.8 for 3 h at 28°C. Purifications were performed 
according to manufacturer instructions using the nickel-charged resin Ni-NTA (Qiagen, 
Courtaboeuf, France) for His-Tagged proteins or Glutathione sepharose 4B (GE Healthcare 
Europe GmbH, Orsay, France) for GST fusions. Purified His-tagged Krit1 WT and 
KRKK/AAAA were dialyzed and concentrated against 50 mM phosphate buffer pH 8.0, 120 
mM NaCl, 10 % glycerol, DTT 1 mM. All other proteins were dialyzed and concentrated in 20 
mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM MgCl2, and 10% glycerol and supplemented with 20 
µM GDP for His-tagged Rap1. A fraction of purified GST-ICAP-1 was cleaved by thrombin 
according to manufacturer instructions (GE Healthcare). Protein concentration was determined 
by SDS-PAGE and fluorometric analysis of Sypro Orange (Amresco, Interchim, Montluçon, 
France ) stained gel using a Fuji LAS3000 fluorescence imaging system. 
Preloading of Rap1 with GDP or GTPγS - Purified Rap1 was incubated for 45 min at 30°C in 50 
mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM MgCl2, 2 mM EDTA, 10% glycerol and 2 mM 
GTPγS or GDP (Roche Diagnostics). The loaded nucleotide was stabilized in the nucleotide site 
by addition of 5 mM MgCl2. 
GST pull-down - Purified GST-fusions bound to 20 µl of glutathione beads (GE Healthcare) were 
incubated under agitation with purified His-tagged proteins as indicated for 2 h at 4°C in PD 
buffer (50 mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM MgCl2, 10% glycerol, 1% NP-40, 2 mM 
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DTT, protease inhibitors) in a final volume of 50 µl. Beads were washed three times in 1 ml of 
PD buffer and eluted with 30 µl of Laemmli sample buffer. Input and bound proteins were 
analyzed by Sypro Orange (Amresco) staining of the gel or by western blotting. 
Cell culture and transfection: Baby Hamster Kidney (BHK) cells were grown in BHK-21 
medium (Invitrogen BV, Leek, The Netherlands ) containing 5% fetal calf serum, 10% tryptose 
phosphate broth, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Glutamine. The 
cells were transfected with Fugene6 transfection reagent (Roche Diagnostics) according to the 
manufacturer’s instructions. 
FLAG pull-down: BHK cells were transfected with pcDNA4/V5-HISA-FLAG-Krit1. Forty eight 
hours after transfection, cells were washed with PBS and scrapped in PD buffer. After a 15 min 
incubation at 4°C, cells were centrifuged at 14 000g for 30 min at 4°C. The supernatant was 
incubated with mouse anti-FLAG M2 coupled to agarose beads (Sigma Aldrich L'Isle d'Abeau 
Chesnes, France) for 2 hours at 4°C. FLAG-Krit1 trapped on beads was incubated with 3 µM of 
Rap1GTPγS, 7 µM of ICAP-1 or both for 2 hours at 4°C under agitation. Beads were then 
washed three times with PD buffer and bound proteins were eluted with 200 µg/ml of FLAG 
peptide in PD buffer. Input and eluted proteins were analyzed by SDS-PAGE and Sypro Orange 
staining of the gel. 
Microtubule sedimentation experiments: 
-Tubulin purification and polymer preparation: Purified lamb brain tubulin was 
polymerized for 15 min at 37°C in BRB50 buffer (50 mM PIPES pH 6.8, 1mM EGTA, 1 mM 
MgCl2) containing 1 mM GTP, 5 mM MgCl2 and 10 % glycerol [40]. Then, every 10 min, 8, 80, 
and 800 µM taxol were added at 37°C. The mixture was layered onto 28 μl of 50% glycerol in 
BRB50 buffer containing 1 mM GTP and 80 μM taxol and centrifuged at 16000 g for 10 min at 
25°C. The pellet was re-suspended in the same buffer. 
-Sedimentation experiments: Polymerized microtubules corresponding to approximatively 
150 pmoles of tubulin were incubated with the indicated proteins in BRB50 buffer pH 7.5, in 20 
μl for 30 min at 25°C. The reaction mixture was layered onto 20 μl of 30% glycerol in BRB50 
buffer pH 7.5 and centrifuged at 16 000 g for 10 min at 25°C. The pellets were resuspended in 40 
μl of 15 % glycerol in BRB50 buffer pH 7.5. The percentage of proteins cosedimented with 
microtubules was determined by SDS-PAGE and fluorometric analysis of the Sypro Orange 
stained gel using fluorescence imaging or by western blotting. 
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Immunofluorescence and cell microscopy: 
BHK cells were co-transfected with pEYFP-Krit1 and pECFP-tubulin with or without pMT2-
HA-Rap1V12. Twenty-four hours after transfection, cells were fixed in 4% PFA for 20 minutes 
and processed for immunofluorescence analysis as already described [41]. HA-Rap1V12 was 
labelled with 3F10 anti-HA monoclonal antibody (Roche Diagnostics). Confocal microscopy 
analysis was carried out using a Leica TCS-SP5 microscope (Leica Microsystemes SAS, Rueil-
Malmaison, France). 
Asolectin vesicles and liposome sedimentation experiments:  
- Asolectin vesicles and liposomes preparation: Asolectin (Sigma Aldrich) vesicles were 
prepared by the reverse phase method [42] and sucrose-loaded liposomes (plasma membrane 
mix: 40% PC, 15% PE, 20% cholesterol, 25% PS, 0.2 % NBD-PE; 2 mM lipids) were prepared 
by the extrusion method [43]. Lipids in chloroform were purchased from Avanti Polar Lipids 
except for egg PC (Sigma Aldrich) and NBD-PE (Molecular Probes Europe, Leiden, The 
Netherlands) 
- Sedimentation experiments: Proteins were incubated for 20 min at 25 °C with sucrose-
loaded liposomes or asolectin vesicles in 20 mM Tris-HCl pH 8.0, 120 mM NaCl, 1mM MgCl2, 
10 % glycerol, 1 mM DTT and were centrifuged for 20 min at 400000g at 20 °C. The percentage 
of proteins in the supernatant and pellet was determined by fluorometric analysis of the Sypro-
Orange stained gel using fluorescence imaging. 
Modelling of Krit1 FERM domain - The Psi-Blast [44] web tools were used to obtain alignments 
of Krit1 last 300 residues with different template sequences. The structure of radixin (pdb entry; 
1GC6) was used as template for F1 FERM domain and that of talin (pdb entry: 1Y19) for F2 and 
F3 FERM domains. The alignments were improved manually, taking into account the predicted 
secondary structure of Krit1 and the secondary structures of talin and radixin. One hundred 
models of F1, F2 and F3 domains were constructed separately by comparative modelling with 
the MODELLER 7 program [45]. The best model was retained for each FERM domain and the 
side chains were repositioned in optimized conformations, using SCWRL[46] and SCit web 
server [47]. The models were finally subjected to energy minimization. The stability of these 
models was assayed by molecular dynamics simulations using the Gromos 96 force field 
implemented in GROMACS version 3.2.1 [48]. Since there is a good conservation of the spatial 
arrangement of F1-F2-F3 among the cristallized FERM domains, the three modelized Krit1 
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subdomains were manually positioned according to the arrangement of radixin FERM domain. 
Structures were visualized with Pymol (Delano Scientific LLC, USA) 
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FIGURE LEGENDS 
 
Fig. 1. Krit1contains a putative FERM domain and binds to PIP2. 
(A) Radixin-IP3 co-crystal structure. IP3 is in yellow, basic residues of F1 (K53, K60, K63, 
K64) and F3 (R273, R275, R279) domains are in red. The Tryptophan W58 is in green. (B) 
Homology models of F1, F2 and F3 domains of Krit1. The three independently modeled sub-
domains have been manually arranged as on radixin structure. Basic residues of F1 (K475, K479, 
R485) and F3 (K713, K720, K724) domains are in red. The Tryptophan W487 is in green. 
(C) Krit1 (1 μM) was incubated with plasma membrane mix liposomes (0.75 mM) containing or 
not 2 % PIP2 at various NaCl concentrations. After centrifugation, proteins present in the 
supernatant (S) and the pellet (P) were analyzed by SDS-PAGE and quantified by fluorometry. 
Protein precipitation in the absence of liposomes has been substracted. Bands below Krit1 band 
are E.Coli contaminants that also bind to PIP2. 
 
Fig.2. Krit1 N and C terminal parts associate together via the NPAY motif and ICAP-1 disrupts 
this association.  
(A) Schematic representation of Krit1 fragments used. FERM domain : Four-point one, Ezrin, 
Radixin, Moesin; PTB-like: Phosphotyrosine-binding domain. ANK: Ankyrin repeats. (B) GST-
pull-down of 100 nM Krit1-NTer WT or mutant on 100 nM GST-HypoKrit1 or GST alone 
following the experimental procedure detailed in material and methods. (C). GST-pull-down of 5 
µM Krit1-NTer on 3.5 µM GST-HypoKrit1 in presence of 5 µM ICAP-1. In (A) GST-fusions 
were immunoblotted with GST antibodies. In (B) and (C), GST-fusions were stained with 
Ponceau Red. Krit1-NTer and ICAP-1 were immunoblotted with His-tag and ICAP-1 antibodies 
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respectively. Inputs correspond to 1/20 of total proteins. These results are representative of three 
independent experiments. 
 
Fig. 3. Rap1 binds to Krit1 C-terminus preferentially in its Rap1GTP form. 
(A) GST-pull down of 1 µM Rap1GDP, Rap1GTPγS or H-RasGTPγS on 10 µM GST-
HypoKrit1 or GST alone. Inputs correspond to 1/25 of total proteins. GST-fusions were 
immunoblotted with GST antibodies. Rap1, ICAP-1 and H-Ras were immunoblotted with His-
tag, ICAP-1 and H-Ras antibodies respectively. (B) GST-pull down of 1 µM RapGTPγS on 10 
µM GST-HypoKrit1 or 10 µM GST-HypoKrit1ΔC. Input corresponds to 1/4 of total Rap1. Rap1 
was immunoblotted with His-tag antibody. These data are representative of four independent 
experiments. 
 
Fig 4: Krit1, Rap1-GTPγS and ICAP-1 form a ternary complex in vitro. 
GST-pull-down of 5 µM Krit1 or/and 5 µM Rap1GTPγS on 5 µM GST-ICAP-1 fusion or GST 
alone. Krit1 binding to GST-ICAP-1 was visualized by Sypro Orange staining of the gel. Rap1 
binding was visualized by western blot using His-tag antibody. These results were reproduced 
three times.  
 
Fig 5: Rap1 binding to HypoKrit1 is not modified by Krit-Nter or ICAP-1. 
(A) Comparaison by GST- pull down of the binding of 10 µM Rap1GTPγS to 3 µM GST-
HypoKrit1 in the absence or presence of 10 µM Krit1-Nter and 10 µM ICAP-1. Rap1 and Krit1-
Nter were detected by immunoblotting using anti-His antibody. ICAP-1 was revealed by anti-
ICAP-1 antibody. (B) FLAG-pull down of 3 µM Rap1GTPγS or 7 µM GST-ICAP-1 to FLAG-
Krit1 beads. Control corresponds to beads incubated with non transfected BHK cells and 
processed as FLAG-Krit beads. Input corresponds to 1/40 of total proteins. Proteins were stained 
by Sypro Orange.  
These results are representative of three independent experiments. 
(C) Model of the conformation of Krit1 in a binary complex with Rap1 or in a ternary complex 
with Rap1 and ICAP-1. Rap1 binds to the C-terminus of Krit1 closed and opened conformations. 
ICAP-1 binding opens Krit1 without perturbing Rap1 binding. For the clarity of the 
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representation only intramolecular folding has been represented. A head to tail intermolecular 
folding between two molecules of Krit1 is however not excluded. 
 
Fig. 6. Krit1 interacts directly with microtubules in vitro via two sites in its N- and C-termini and 
Rap1 and ICAP-1 inhibits this interaction.  
In each experiment, 40 pmoles of Krit1 were incubated in the absence or presence of taxol-
stabilized MT polymerized in vitro from 150 pmoles of purified tubulin and centrifuged on 
sucrose gradient. Supernatant (S) and pellet (P) were analyzed by SDS-PAGE and the percentage 
of Krit1 bound to MT quantified by fluorometry. Krit1 precipitation in the absence of MT has 
been substracted. 
(A) Identification of MT binding sites on Krit1 using different Krit1 mutants. Arrowheads 
indicate Krit1 WT or mutants, T: Tubulin. Each experiment was repeated between two to four 
times. 
(B) Inhibition of Krit1 binding to MT by Rap1 and ICAP-1. 200 pmoles of Rap1 or ICAP-1 were 
added to 40 pmoles of Krit1 and to polymerized MT. Each experiment was repeated three times. 
 
Fig7. YFP-Krit1 co-localizes with CFP-labelled microtubules in transfected BHK cells and is 
delocalized by activated Rap1. BHK-cells were transfected with plasmids encoding YFP-Krit1 or 
YFP-ARNO and CFP-tubulin (A) together with pMT2HA-Rap1V12 (B) HA-Rap1V12 was 
detected with anti-HA 3F10 antibody.  Scale bars: 15 μm. 
 
Fig. 8. Rap1 stimulates Krit1 binding to membranes. 
(A) GST-HypoKrit1 (0.5 µM) was incubated with asolectin vesicles (1 mg/ml) in absence or 
presence of Rap1GTPγS (3 µM). After centrifugation, the supernatant (S) and the pellet (P) were 
analyzed by SDS-PAGE and quantified by fluorometry. Protein precipitation in absence of 
liposomes has been substracted. (B) Dose-response of stimulation of Krit1 binding to asolectin 
vesicles by increasing concentrations of Rap1GTPγS. Each experiment was reproduced three 
times. 
 
Fig 9. Model of regulation of Krit1 binding to microtubules and plasma membrane. 
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In the cell, Krit1 would be transported in its closed conformation along the microtubules toward 
the plasma membrane. When reaching the membrane, Krit1 would detach from MT and be 
captured by activated Rap1 and ICAP-1 on the plasma membrane. 
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